Catalog No.
DHC22402
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG2-kappa
Clonality
Monoclonal
Target
CCP, PDN-21, CALCA, Calcitonin carboxyl-terminal peptide, Calcitonin, CALC1, Calcitonin gene-related peptide II, CALCB, Calcitonin gene-related peptide 2, Beta-CGRP, CALC2, CGRP-II, Beta-type CGRP
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01258 & P10092
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
LBR-101, PF-04427429, RI-307, RN-307, TEV-48125, fremanezumab-vfrm, CAS: 1655501-53-3
Clone ID
Fremanezumab
Fremanezumab for the Preventive Treatment of Chronic Migraine, PMID: 29171818
Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine, PMID: 32832978
Fremanezumab for migraine, PMID: 32346217
Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial, PMID: 29800211
Fremanezumab for the prevention of chronic and episodic migraine, PMID: 31050694
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial, PMID: 31427046
Fremanezumab for the preventive treatment of migraine, PMID: 31177856
Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study, PMID: 32913018
From LBR-101 to Fremanezumab for Migraine, PMID: 30311143
Fremanezumab as a preventive treatment for episodic and chronic migraine, PMID: 31043094
Fremanezumab, PMID: 31644089
An Evidence-Based Review of Fremanezumab for the Treatment of Migraine, PMID: 32222952
Fremanezumab for the preventive treatment of migraine in adults, PMID: 31220963
Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine, PMID: 31675102
The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study, PMID: 32958075
Fremanezumab (Ajovy) and galcanezumab (Emgality) for migraine prevention, PMID: 30681655
Fremanezumab, PMID: 30371997
No "Wearing-Off Effect" Seen in Quarterly or Monthly Dosing of Fremanezumab: Subanalysis of a Randomized Long-Term Study, PMID: 33009665
Migraine overview and summary of current and emerging treatment options, PMID: 30681821
Fremanezumab: First Global Approval, PMID: 30406901
Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials, PMID: 33413075
Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database, PMID: 33435709
Effect of fremanezumab on quality of life and productivity in patients with chronic migraine, PMID: 32747522
Fremanezumab for preventive treatment of migraine: Functional status on headache-free days, PMID: 30120138
A comprehensive overview and safety evaluation of fremanezumab as a preventive therapy for migraine, PMID: 32116061
Fremanezumab for migraine prevention: more effective, less costly, PMID: 32501385
Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials, PMID: 33136176
Fremanezumab in the treatment of migraines: evidence to date, PMID: 31686900
Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials, PMID: 32508742
Effect of Fremanezumab Monthly and Quarterly Doses on Efficacy Responses, PMID: 32445498
Fremanezumab blocks CGRP induced dilatation in human cerebral, middle meningeal and abdominal arteries, PMID: 30109438
Do Treatment Strategies of Fremanezumab Have Similar Effect on Migraine?, PMID: 32011737
Fremanezumab inhibits vasodilatory effects of CGRP and capsaicin in rat cerebral artery - Potential role in conditions of severe vasoconstriction, PMID: 31589869
Monoclonal antibodies for the prevention of migraine, PMID: 31550937
Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study, PMID: 32887548
Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine, PMID: 31752521
CGRP as the target of new migraine therapies - successful translation from bench to clinic, PMID: 29691490
CGRP Antibodies as Prophylaxis in Migraine, PMID: 30550780
Correction to: Fremanezumab: First Global Approval, PMID: 30859411
Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials, PMID: 30977520
What's New in the Treatment of Migraine?, PMID: 31393282
Drugs for Migraine, PMID: 33434187
Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine, PMID: 31418911
Current and emerging evidence-based treatment options in chronic migraine: a narrative review, PMID: 31470791
Role of CGRP in Migraine, PMID: 30725283
Fremanezumab and its isotype slow propagation rate and shorten cortical recovery period but do not prevent occurrence of cortical spreading depression in rats with compromised blood-brain barrier, PMID: 31895266
Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines, PMID: 28862758
Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain, PMID: 32484365
Antibodies to watch in 2019, PMID: 30516432
Baloxavir marboxil, Fremanezumab-vfrm, Galcanezumab-gnlm, and Lofexidine hydrochloride, PMID: 30580925
For research use only. Not for human or drug use.
